5-溴-1-甲基-1H-苯并[d]咪唑 | 53484-15-4

• 物质功能分类: 医药中间体 - 杂环化合物
• 分子结构分类: 有机化合物 - 有机杂环化合物 - 苯并咪唑类
• 中文名称: 5-溴-1-甲基-1H-苯并[d]咪唑
• 中文别名: 5-溴-1-甲基苯并咪唑
• 英文名称: 5-bromo-1-methyl-1H-benzo[d]imidazole
• 英文别名: 5-bromo-1-methyl-1H-1,3-benzodiazole；5-bromo-1-methyl-benzoimidazole；5-bromo-1-methylbenzimidazole
• CAS: 53484-15-4
• 化学式: C₈H₇BrN₂
• mdl: MFCD09878409
• 分子量: 211.061
• InChiKey: KMJMDIYGNFGEEO-UHFFFAOYSA-N

物化性质

• 沸点：
  317.2±34.0 °C(Predicted)
• 密度：
  1.60

计算性质

• 辛醇/水分配系数(LogP)：
  2.1
• 重原子数：
  11
• 可旋转键数：
  0
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.125
• 拓扑面积：
  17.8
• 氢给体数：
  0
• 氢受体数：
  1

安全信息

• 海关编码：
  2933990090
• 危险性防范说明：
  P261,P305+P351+P338
• 危险性描述：
  H302,H315,H319,H335
• 储存条件：
  室温下应保持干燥和密封保存。

SDS

Material Safety Data Sheet

---

Section 1. Identification of the substance
Product Name: 5-Bromo-1-methyl-1H-benzo[d]imidazole
Synonyms:

---

Section 2. Hazards identification
Harmful by inhalation, in contact with skin, and if swallowed.

---

Section 3. Composition/information on ingredients.
Ingredient name: 5-Bromo-1-methyl-1H-benzo[d]imidazole
CAS number: 53484-15-4

---

Section 4. First aid measures
Skin contact: Immediately wash skin with copious amounts of water for at least 15 minutes while removing
contaminated clothing and shoes. If irritation persists, seek medical attention.
Eye contact: Immediately wash skin with copious amounts of water for at least 15 minutes. Assure adequate
flushing of the eyes by separating the eyelids with fingers. If irritation persists, seek medical
attention.
Inhalation: Remove to fresh air. In severe cases or if symptoms persist, seek medical attention.
Ingestion: Wash out mouth with copious amounts of water for at least 15 minutes. Seek medical attention.

---

Section 5. Fire fighting measures
In the event of a fire involving this material, alone or in combination with other materials, use dry
powder or carbon dioxide extinguishers. Protective clothing and self-contained breathing apparatus
should be worn.

---

Section 6. Accidental release measures
Personal precautions: Wear suitable personal protective equipment which performs satisfactorily and meets local/state/national
standards.
Respiratory precaution: Wear approved mask/respirator
Hand precaution: Wear suitable gloves/gauntlets
Skin protection: Wear suitable protective clothing
Eye protection: Wear suitable eye protection
Methods for cleaning up: Mix with sand or similar inert absorbent material, sweep up and keep in a tightly closed container
for disposal. See section 12.
Environmental precautions: Do not allow material to enter drains or water courses.

---

Section 7. Handling and storage
Handling: This product should be handled only by, or under the close supervision of, those properly qualified
in the handling and use of potentially hazardous chemicals, who should take into account the fire,
health and chemical hazard data given on this sheet.
Store in closed vessels.
Storage:

---

Section 8. Exposure Controls / Personal protection
Engineering Controls: Use only in a chemical fume hood.
Personal protective equipment: Wear laboratory clothing, chemical-resistant gloves and safety goggles.
General hydiene measures: Wash thoroughly after handling. Wash contaminated clothing before reuse.

---

Section 9. Physical and chemical properties
Appearance: Not specified
Boiling point: No data
No data
Melting point:
Flash point: No data
Density: No data
Molecular formula: C8H7BrN2
Molecular weight: 211.1

---

Section 10. Stability and reactivity
Conditions to avoid: Heat, flames and sparks.
Materials to avoid: Oxidizing agents.
Possible hazardous combustion products: Carbon monoxide, nitrogen oxides, hydrogen bromide.

---

Section 11. Toxicological information
No data.

---

Section 12. Ecological information
No data.

---

Section 13. Disposal consideration
Arrange disposal as special waste, by licensed disposal company, in consultation with local waste
disposal authority, in accordance with national and regional regulations.

---

Section 14. Transportation information
Non-harzardous for air and ground transportation.

---

Section 15. Regulatory information
No chemicals in this material are subject to the reporting requirements of SARA Title III, Section
302, or have known CAS numbers that exceed the threshold reporting levels established by SARA
Title III, Section 313.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

制备方法与用途

应用

5-溴-1-甲基苯并咪唑可用作有机合成中间体和医药中间体，主要用于实验室研发过程和化工生产过程中。

制备

在26 mmol化合物5-溴-2-(甲基氨基)苯胺和50 mL二甲苯的混合物中加入7.7 mmol原甲酸三乙酯。所得悬浊液加热回流7小时后冷却，抽滤得到固体，再溶于90 mL二氯甲烷中。该溶液依次用50 mL 10%碳酸钾和50 mL饱和食盐水各洗涤一次，然后使用无水硫酸镁干燥。减压蒸出溶剂后，将剩余的液体浓缩至干，并再次溶于二氯甲烷中，采用相同的方法进行洗涤和干燥以回收有机物。合并后的有机物通过硅胶柱层析，洗脱剂为石油醚/乙酸乙酯（3∶1），最终得到5-溴-1-甲基苯并咪唑6.5 g，收率为87%。

反应信息

• 作为反应物：
  描述：

  5-溴-1-甲基-1H-苯并[d]咪唑 在 盐酸 、 tris-(dibenzylideneacetone)dipalladium(0) 、 palladium diacetate 、 R-(+)-1,1'-联萘-2,2'-双二苯膦 、 sodium t-butanolate 作用下， 以 乙酸乙酯 为溶剂， 反应 7.0h， 生成 1-甲基苯并咪唑-5-胺
  参考文献：
  名称：

  取代的杂芳基化合物及其组合物和用途

  摘要：

  本发明公开了取代的杂芳基化合物及其组合物和它们的用途。所述化合物为式(I)所示的化合物或者式(I)所示化合物的立体异构体、互变异构体、氮氧化物、溶剂化物、代谢产物、药学上可接受的盐或它的前药。本发明还提供了包含所述化合物的药物组合物，所述化合物和药物组合物可以调节蛋白激酶，尤其是Aurora激酶和JAK激酶的活性，用于预防、处理、治疗和减轻蛋白激酶，尤其是JAK激酶活性介导的疾病或紊乱。

  公开号：

  CN109776522B
• 作为产物：
  描述：

  4-溴-N-甲基-2-硝基苯胺 在 盐酸 、 铁粉 、 氯化铵 作用下， 以 乙醇 、 水 为溶剂， 生成 5-溴-1-甲基-1H-苯并[d]咪唑
  参考文献：
  名称：

  Cu催化苯并咪唑与艾伦的C-H烯丙基化

  摘要：

  已经描述了 CuH 催化的苯并咪唑与丙二烯的分子内环化和分子间烯丙基化。在Cu(OAc) 2 /Xantphos的催化体系和催化量的(MeO) 2 MeSiH的作用下，反应顺利进行。该协议具有温和的反应条件和对带有吸电子、给电子或电子中性基团的底物的良好耐受性。针对该氢化铜催化体系提出了一种新的催化机理。

  DOI：

  10.1021/acs.orglett.1c02346

文献信息

• 4-AZETIDINYL-1-PHENYL-CYCLOHEXANE ANTAGONISTS OF CCR2
  申请人：Zhang Xuqing

  公开号：US20100267689A1

  公开（公告）日：2010-10-21

  The present invention comprises compounds of Formula (I): wherein: X, R 1 , R 2 , R 3 , and R 4 are as defined in the specification. The invention also comprises a method of preventing, treating or ameliorating a syndrome, disorder or disease, wherein said syndrome, disorder or disease is type II diabetes, obesity and asthma. The invention also comprises a method of inhibiting CCR2 activity in a mammal by administration of a therapeutically effective amount of at least one compound of Formula (I).

  本发明涵盖了以下式（I）的化合物： 其中：X，R1，R2，R3和R4如规范中所定义。该发明还涵盖了一种预防、治疗或改善综合征、疾病或疾病的方法，其中所述综合征、疾病或疾病是II型糖尿病、肥胖和哮喘。该发明还涵盖了通过给哺乳动物施用至少一种式（I）化合物的治疗有效量来抑制CCR2活性的方法。
• Endogenous X–CO species enable catalyst-free formylation prerequisite for CO₂ reductive upgrading
  作者：Hongguo Wu、Wenshuai Dai、Shunmugavel Saravanamurugan、Hu Li、Song Yang

  DOI：10.1039/d0gc02142c

  日期：——

  (>90%) from catalyst-free reductive upgrading of CO2 under mild conditions (50 °C). The endogenous X–CO species, derived from the N-methyl-substituted amide-based solvent [Me2N–C(O)–R], especially PolarClean, and O-formyl group [O–C(O)–H] of in situ formed silyl formate, were found to play a prominent promotional role in the activation of the used hydrosilane for reductive CO2 insertion, as demonstrated

  CO 2是温室气体的主要成分，目前已被开发为一种有前途的碳原料替代品。在各种转化途径中，经历催化还原的CO 2可以提供氢/能量载体和增值化学品，而特定的含金属催化剂或有机催化剂通常是顺利进行所涉及的反应过程的先决条件。在这项工作中，可以在温和的条件下通过无催化剂的CO 2还原提质，以高收率（> 90％）合成甲酸和含N的苯并杂环化合物（包括各种苯并咪唑，苯并噻唑和苯并恶唑）以及硅烷醇。50°C）。来自N的内源X–C O物种甲基取代的酰胺基溶剂[Me 2 N–C（O）–R]，尤其是PolarClean，以及原位形成的甲硅烷基甲酸酯的O-甲酰基[ OC – O （H）–H]如密度泛函理论（DFT）计算和同位素标记实验所证明的那样，在用于还原的CO 2插入的已用氢硅烷的活化中，显着的促进作用。此外，还描述了反应机理和基于条件的敏感性评估。
• [EN] SUBSTITUTED HETEROARYL COMPOUNDS AND METHODS OF USE<br/>[FR] COMPOSÉS HÉTÉROARYLE SUBSTITUÉS ET LEURS MÉTHODES D'UTILISATION
  申请人：SUNSHINE LAKE PHARMA CO LTD

  公开号：WO2019099311A1

  公开（公告）日：2019-05-23

  The present invention provides novel heteroaryl compounds, pharmaceutical acceptable salts and formulations thereof. They are useful in preventing, managing, treating or lessening the severity of a protein kinase-mediated disease. The invention also provides pharmaceutically acceptable compositions comprising such compounds and methods of using the compositions in the treatment of protein kinase-mediated disease.

  本发明提供了新颖的杂环芳基化合物，其药用盐和制剂。它们在预防、管理、治疗或减轻蛋白激酶介导的疾病的严重程度方面是有用的。该发明还提供了包括这些化合物的药用组合物以及使用这些组合物治疗蛋白激酶介导的疾病的方法。
• Visible Light-Promoted Aliphatic C–H Arylation Using Selectfluor as a Hydrogen Atom Transfer Reagent
  作者：Hong Zhao、Jian Jin

  DOI：10.1021/acs.orglett.9b01635

  日期：2019.8.16

  A mild, practical method for direct arylation of unactivated C(sp3)–H bonds with heteroarenes has been achieved via photochemistry. Selectfluor is used as a hydrogen atom transfer reagent under visible light irradiation. A diverse range of chemical feedstocks, such as alkanes, ketones, esters, and ethers, and complex molecules readily undergo intermolecular C(sp3)–C(sp2) bond formation. Moreover, a

  通过光化学已经实现了一种温和的，实用的方法，用于将未激活的C（sp 3）–H键与杂芳烃直接芳基化。Selectfluor在可见光照射下用作氢原子转移试剂。各种各样的化学原料，例如烷烃，酮，酯和醚，以及复杂的分子容易形成分子间的C（sp 3）–C（sp 2）键。此外，可通过此处介绍的方案有效地烷基化各种杂芳烃，包括药学上有用的支架。
• Inhibitors of CYP 17
  申请人：BOCK Mark G.

  公开号：US20100331326A1

  公开（公告）日：2010-12-30

  The present invention provides compounds of Formula (I) and (II), or a pharmaceutically acceptable salts thereof, where R 53 , R 54 , p, q, and n are as defined herein. The compounds of the present invention have been found to be useful as 17α-hydroxylase/C 17,20 -lyase inhibitors.

  本发明提供了式(I)和(II)的化合物，或其药用可接受的盐， 其中R 53 ，R 54 ，p，q和n如本文所述定义。本发明的化合物被发现作为17α-羟化酶/C 17,20 -裂解酶抑制剂是有用的。